Theranos Inc., the embattled blood-diagnostics firm, is on the ropes. The Silicon Valley company had $200 million of cash on hand at the end of 2016, people familiar with the matter said, less than a quarter of the funding it raised from investors and partners. The number was disclosed in a conference call with investors last month. Investors also were told the firm didn’t generate any material revenue in 2015 and 2016 and...

Source: Wall Street Journal February 16, 2017 20:37 UTC